Navigation Links
Covagen Names Elias Papatheodorou Chief Business Officer
Date:4/14/2013

ZURICH-SCHLIEREN, Switzerland, April 15, 2013 /PRNewswire/ -- Covagen today announced the expansion of its senior management team with the appointment of Elias Papatheodorou as chief business officer. He brings 20 years of work experience including 13 years in the life science sector with a track record of fundraising and collaborative agreements.

Prior to joining Covagen, Mr. Papatheodorou was senior vice president business development and operations at Medigene where he led the business development efforts for the company's pipeline and technology and closed the Asian-Australian licensing agreement for Medigene's lead oncology asset to Syncore. Prior to Medigene, Mr. Papatheodorou was chief executive officer of Novosom where he completed a series of collaborative agreements with pharmaceutical companies in Europe, U.S. and Asia, led the company's fundraising activities and ultimately closed the sale of Novosom's Smarticles technology to Marina Biotech. Mr. Papatheodorou was also vice president of business development and marketing for the medical imaging company A.T.I. and held positions of increasing responsibility at The Coca-Cola Company and Philip Morris.

"We are fortunate to have someone with Elias' experience join our executive team, particularly as we continue to validate our bispecific FynomAb™ technology and prepare to bring our lead drug candidate COVA322, a bispecific TNF/IL-17A inhibitor, into the clinic," said Franz Hefti , chairman of the board of Covagen. "The flexibility of the architecture of our FynomAbs is unique in bispecific technology and Elias will play a key role in advancing discussions with potential partners."

Mr. Papatheodorou holds a bachelor's degree from Ithaca College and graduate education from Cornell University.

About CovagenCovagen develops bispecific FynomAbs™ by fusing its human Fynomer™ binding proteins to antibodies resulting in therapeutics with novel modes-of-action and enhanced efficacy in the treatment of inflammatory diseases and cancer. The ability to fuse Fynomers™ to multiple sites on an antibody allows Covagen to create FynomAbs™ with tailored architecture to maximize efficacy. FynomAbs™ maintain the advantageous drug-like properties of antibodies such as excellent stability and long half-life. Covagen is actively moving COVA322, its lead bispecific anti-TNF/IL-17A FynomAb™, through development and expects to initiate a Phase I/IIa trial in patients with psoriasis in the first quarter of 2014.

For more information, please visit www.covagen.com.Corporate Contact:

Media Contact:Julian Bertschinger, Ph.D.Matt Middleman, M.D.Chief Executive OfficerRusso PartnersTel: +41 (0) 44 732 4Tel: +1 212 845 4272info@covagen.commatt.middleman@russopartnersllc.com 


'/>"/>
SOURCE Covagen
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. IDEXX Laboratories Names Jeffrey Fiarman Executive Vice President and General Counsel
2. Collegium Pharmaceutical Names Douglas Carlson to Vice President of Business Development
3. Quest Diagnostics Names Sukumar Nagendran, M.D., Vice President, Medical Affairs
4. Halozyme Therapeutics Names Matt Posard to Board of Directors
5. Array BioPharma Names Michael N. Needle, M.D. As Chief Medical Officer
6. Bausch + Lomb Names Robert Bertolini President And Chief Financial Officer
7. Tandem Diabetes Care Names Lonnie Smith As Chairman Of The Board
8. PeriGen, Inc. Names American Journal of OBGYN Editor-In-Chief Thomas J. Garite MD, Chief Clinical Officer
9. Dynamic Healthcare Services Names Senior Level Management Team
10. Hello Health Inc. Names Barry Holleman Executive Vice President, Chief Operating Officer
11. SkilaMederi Names Ray Joske as Chief Commercial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... , February 17, 2017 ... the S&P 500 edged lower at the closing bell, ... streak above the 20,000 benchmark. Moreover, five out of ... Taking into consideration yesterday,s market sentiment, Stock-Callers.com assessed the ... & Nephew PLC (NYSE: SNN ), ABIOMED ...
(Date:2/16/2017)... Research and Markets has announced the ... Technologies" report to their offering. ... Traditional medical devices include ... non-drug coated implantables, large endoscopes, needle based drug delivery, lab ... last two to three decades for the treatment and management ...
(Date:2/16/2017)... -- The global preparative and process chromatography market is ... USD 5.49 billion in 2016, at a CAGR of ... the preparative and process chromatography market is segmented into ... chromatography segment is expected to account for the largest ... in this segment can primarily be attributed to the ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... Like most hospitals across ... Driven in large part by the Hospital Readmission Reduction Program (HRRP), the return of ... focus area for hospitals across the nation. While many providers are struggling to leverage ...
(Date:2/17/2017)... ... 17, 2017 , ... The Mason Pasquin Agency, a Virginia-based ... owners in and around the Hampton Roads metropolitan region, is joining the local ... domestic violence. , There are multiple categories of domestic violence – physical abuse ...
(Date:2/16/2017)... ... February 17, 2017 , ... Harsha ... 10 years of research, development and clinical trials, the founder of Chigurupati Technologies ... patented compound of FDA approved ingredients that when infused into alcohol, protect the ...
(Date:2/16/2017)... ... 17, 2017 , ... Teaching nursing care of vulnerable children is the focus ... is being created with the support of the Hearst Foundations. An initiative of the ... address what has been identified as a critical gap in preparing the next generation ...
(Date:2/16/2017)... Mt. Kisco, New York (PRWEB) , ... February ... ... Westchester Hospital’s (NWH) nursing professionalism, teamwork and superiority in patient care, NWH ... Chair of the Commission on Magnet on Tuesday, January 31, 2017. The American ...
Breaking Medicine News(10 mins):